Regulus Therapeutics Inc. financial data

Symbol
RGLS on Nasdaq
Industry
Pharmaceutical Preparations
Location
4224 Campus Point Court, Suite 210, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 957 % +122%
Debt-to-equity 12.4 % -64.1%
Return On Equity -55.5 % +35%
Return On Assets -49.4 % +22.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.5M shares +236%
Common Stock, Shares, Outstanding 65.5M shares +236%
Entity Public Float 27.4M USD -5.52%
Common Stock, Value, Issued 65K USD +242%
Weighted Average Number of Shares Outstanding, Basic 64.5M shares +237%
Weighted Average Number of Shares Outstanding, Diluted 64.5M shares +237%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 25.6M USD +28.5%
General and Administrative Expense 11.9M USD +28.7%
Operating Income (Loss) -37.5M USD -28.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -35.4M USD -24.2%
Income Tax Expense (Benefit) 1K USD 0%
Net Income (Loss) Attributable to Parent -35.4M USD -24.2%
Earnings Per Share, Basic 1.91 USD/shares -5.91%
Earnings Per Share, Diluted 1.91 USD/shares -5.91%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.1M USD -54.1%
Cash, Cash Equivalents, and Short-term Investments 95.9M USD +157%
Other Assets, Current 2.63M USD +157%
Assets, Current 100M USD +143%
Property, Plant and Equipment, Net 1.08M USD +125%
Operating Lease, Right-of-Use Asset 1.18M USD -33%
Intangible Assets, Net (Excluding Goodwill) 27K USD -30.8%
Other Assets, Noncurrent 21K USD
Assets 104M USD +139%
Accounts Payable, Current 601K USD +66%
Employee-related Liabilities, Current 1.87M USD +22.2%
Accrued Liabilities, Current 923K USD +48.2%
Liabilities, Current 5.26M USD -36%
Operating Lease, Liability, Noncurrent 675K USD -52.5%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 5.94M USD -38.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -87K USD
Retained Earnings (Accumulated Deficit) -533M USD -7.12%
Stockholders' Equity Attributable to Parent 98.2M USD +189%
Liabilities and Equity 104M USD +139%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.74M USD -7.74%
Net Cash Provided by (Used in) Financing Activities 93.1M USD
Net Cash Provided by (Used in) Investing Activities -78.5M USD -624%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 65.5M shares +236%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 5.82M USD -4.29%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17.2M USD -54%
Interest Paid, Excluding Capitalized Interest, Operating Activities 45K USD -69.6%
Deferred Tax Assets, Valuation Allowance 140M USD +6.11%
Deferred Tax Assets, Gross 141M USD +5.96%
Operating Lease, Liability 1.42M USD -32.4%
Payments to Acquire Property, Plant, and Equipment 229K USD +22800%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -35.5M USD -24.7%
Lessee, Operating Lease, Liability, to be Paid 1.51M USD -34.4%
Property, Plant and Equipment, Gross 5.31M USD +7.08%
Operating Lease, Liability, Current 747K USD +9.69%
Lessee, Operating Lease, Liability, to be Paid, Year Two 277K USD -66.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 824K USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 83K USD -56.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 277K USD -66.4%
Deferred Tax Assets, Operating Loss Carryforwards 92.6M USD +2.8%
Unrecognized Tax Benefits 6.25M USD +8.04%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Depreciation, Depletion and Amortization 81K USD +68.8%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 4.86M USD +214%
Interest Expense 500K USD -30.4%